Poolbeg Pharma Share Discussion Threads

[pogue] 01/8/2024 10:36

Peterrr
Selling a drug is selling a drug it's all about market knowledge the stage in it's trails cycle it is at is somewhat irrelevant. You are either a sales person or you are not. You suggested we had too many people not seeing how having no sales team is a good idea
The are spending cash on buying in drugs. Not a lot but never the less cash is being used and brought in from grants.
Legal wise they are constantly applying for patents plus they have to draw up contracts for taking in new drugs plus drawing up contracts for partnering. I suggest a contract for partnering is being orepared just now as part of the trails contract for POLB001. Add in the proposed move to NASDAQ and I think there is a lot of need for a house legal.

[baldrick1] 01/8/2024 10:00

That means you are buying shorts;)

[joseph moran] 01/8/2024 09:56

A lot of the marked sells are infact buys as I can buy for £0.1176 which is same as the marked sells.

[peterrr3] 01/8/2024 03:59

Hi PogueThe team they have assembled is for a coy with a market ready drug or a bunch of late stage 2s. So it ain't POLB.Somehow they need both a CFO and a Controller to pay the corporate credit card bill? They aren't spending on much else. Must be a dream job for those two.They need in house legal when they outsource the technical legals anyway? You need these when you have a sufficient level of interest to get something in writing and there are plenty of decent law firms to hand you don't have to pay full time. In house legal always get deals checked by third parties anyway.They need a Business Manager when they don't have a business? What business can they generate? The only people any pharma could be interested in seeing in the CEO and trial/science leads.

[chica1] 31/7/2024 14:39

The Amryt team aren't replacing anyone.Its just there was no one there.Its was just Jeremy and a few partime executives aligned with Hvivo and Raglan Capital.
Looks to me that POLB001 was going nowhere and they couldn't get the funding to advance it in the clinical trial process for severe flu,hence the U-turn.

It'll take alot more than 6 months and one mini trial to prove its effective against CRS.

'Simple Trial' lol
Huge difference between testing in the lab and testing it on humans that are immunocompromised.

[pogue] 31/7/2024 14:11

Peter
Can you name the dead wood? Those in from Amryt are replacing the last team who failed to get POLB001 over the line with the last pharma looking at it for respiratory applications. It's all about who you know and how to structure a deal former Amryt employees proved that they have the talent. If this cancer deal goes over the line it will put a rocket under the stock as the market for these cancer drugs is in the £billions. The Amryt team have found the pharmas for this potential deal all we are waiting on there is a simple trial to prove that POLB001 does not interfere with the cancer drugs.
Where is the dead wood?

[chica1] 31/7/2024 10:53

Hey nobody knows but there's only 1 qualified chemist in the company and that's Jeremy. Normally at this stage a company like Poolbeg should at least have a CMO.
POLB001 only got repurposed for Cytokine Release Syndrome at the backend of last year.
As I said before Luke O'Neill (even though he's only an advisor) is the main reason I'm holding here because he's one of the top Inflammatory lab chemists in the world.So maybe they saw something in preliminary testing.
I can see they're trying to replicate Amryt's business model but trying to find a distressed US based pharma (as Amryt did with Aegerion) with 2 FDA approved (revenue generating) drugs will not be easy.

I don't think reversing into Silk Road a company that has a Phase 2 candidate for oral ulcers is the answer either.

[peterrr3] 31/7/2024 10:22

Chica I am with you on this. Plenty of unnecessary dead wood in POLB at this stage of the game. They won't be part of the technical decision making and sound unconvincing in the presentations.

[klosters65] 30/7/2024 17:02

Chica, My knowledge does not justify my getting into a deep debate. CF has an extremely valuable large holding in POLB and he has put together a team to run the company. His ability to appoint hugely successful individuals cannot be disputed.Witness – Mo Khan at Hvivo.

[chica1] 30/7/2024 15:03

Well David Allmond failed drastically as CEO at Novacyt.
Only lasted a year,the BOD couldn't get him out fast enough it would seem.
The Amryt hires were the B-Team.
Wiley and Nealon were the A team..That's why they got the huge share option's.



Novacyt Group

Paris, France and Camberley, UK – 10 November 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that David Allmond is stepping down as Chief Executive Officer (CEO) and a member of the Board of Novacyt, with immediate effect, to enable him to pursue other business opportunities. James McCarthy, currently the Company’s Chief Financial Officer (CFO), will assume the role of Acting CEO until a successor is appointed. Steve Gibson, Group Finance Director, will take on a substantial part of the CFO responsibilities to assist James in this period.

The Company remains focused on executing its post-COVID-19 growth strategy to become a leading, global clinical diagnostics company in the fight against infectious diseases through product portfolio expansion, geographic expansion, and business development.

[klosters65] 30/7/2024 12:03

The Amryt Pharma team did not join POLB without good reason. I met David Allmond. Very impressive and will contribute to pushing the company into being successful.

[chica1] 29/7/2024 17:07

Klosters..Why?

Please expand?

And I still hold 1/2 my distribution shares which is probably way too much..
The only reason I'm holding is Jeremy and Poolbeg's advisor Luke O'Neill and their success at Inflazome.

But here is
Inflazome Management before it was acquired by Roche.. Jeremy's role was business development.
hxxps://www.inflazome.com/about-us

Compare that to Poolbeg's current management
hxxps://www.poolbegpharma.com/about/leadership/

Jeremy is the only Biochemist.
No Chief Medical Officer or Scientific Officer.
There are also some part-time executives on the management team.In fact most are including the Executive Chairman.
Top heavy on Sales on Financial positions imho.

[klosters65] 29/7/2024 16:46

baldi, Maybe not exactly top of the class. However, entertaining whilst we wait There is in all probability a very healthy profit to be made between now and Christmas by buying and holding this share.

[baldrick1] 29/7/2024 07:09

Who will be buying at 8-10p ??

[1gw] 26/7/2024 17:34

It's a wind-up. Poolbeg chimneys being repainted.

[anderson3] 26/7/2024 17:20

Chica, can’t access, what is it

[chica1] 26/7/2024 14:52

Very interesting news..the picture is getting clearer.

www.rte.ie/news/dublin/2024/0726/1461841-poolbeg/

[chica1] 26/7/2024 11:09

Was just looking at Jeremy Skillington's previous company Inflazome that was acquired by Roche Labs in 2020
It's interesting there has been absolutely no progress in 4 years.The 2 drugs candidates acquired are still only in Phase 1.

Also interesting
Jeremy Skillington CFO and Ian O’Connell CFO and Executive Chairman Cathal Friel are all based in Dublin.

[chica1] 26/7/2024 08:01

Baldy you could be right about a placing.
Friel now has cash to participate.

Moniman you and Baldy agree on something😁


Or maybe he's going Gold mining in Cyprus..

[chica1] 26/7/2024 08:00

Listing on the Nasdaq pink sheets was a bogus move by Friel,
I said it at the time Nasdaq pinks sheets are where
failed companies die.

[baldrick1] 26/7/2024 07:12

Placings next news imho

[adorling] 26/7/2024 06:49

Good to see they are delisting from the OTC Nasdaq as not only does it save costs but makes the AIM listing the only focus as they implement the new strategy with the ex Amryt Pharma Team.

[baldrick1] 25/7/2024 09:03

Buying at 11.50-12p..be lucky all ;))

[baldrick1] 24/7/2024 16:07

Stringy melting cheese :))

[peterrr3] 24/7/2024 11:49

You sitting this mini pump out Baldrick?